Characterizing the impact of the Covid-19 pandemic on adults with autosomal dominant polycystic kidney disease: a cross-sectional study.

Publication date: Aug 23, 2024

The Covid-19 pandemic greatly affected those with chronic diseases, impacting healthcare access and healthcare seeking behaviors. The impact of the pandemic on adults with Autosomal Dominant Polycystic Kidney Disease (ADPKD) has not been investigated. Participants were recruited from a cohort of 239 ADPKD patients enrolled in a longitudinal study at the University of Maryland. Patients on renal replacement therapy were excluded. N = 66 patients participated in a phone questionnaire from June 2022-December 2022 about ADPKD-related complications, concern about contracting Covid-19, healthcare-seeking behaviors, and telehealth utilization before and after March 2020. N = 34 (51. 5%) of participants reported a positive Covid-19 test result. N = 29 (44%) expressed high concern of contracting Covid-19. Those who avoided medical care at least once (N = 17, 25. 8%) had similar demographics and ADPKD severity to those who did not, but reported greater telehealth utilization (88. 2% vs. 42. 9%, p = 0. 002), greater use of non-prescribed medication for Covid-19 treatment or prevention (35. 3% vs. 8. 2%, p = 0. 01), and were more likely to contract Covid-19 (76. 5% vs. 42. 9%, p = 0. 02). Among the N = 53 who reported very good or excellent ADPKD disease management pre-pandemic, N = 47(89%) reported no significant change during the pandemic. In this highly educated, high-income cohort with a mean age of 46. 1 years, most people reported well-managed ADPKD prior to the pandemic. This may explain why less than half of participants expressed high concern for contracting Covid-19. Overall, there was no significant pandemic-related decline in self-reported ADPKD management. This was likely due to this cohort’s excellent access to, and uptake of, telehealth services. Notably, 1 in 4 participants reported healthcare avoidant behavior, the effect of which may only be seen years from now. Future studies should investigate potential impacts of avoidant behaviors, as well as expand investigation to a more diverse cohort whose care may not have been as easily transitioned to telehealth.

Open Access PDF

Concepts Keywords
December ADPKD
June Adult
Kidney Chronic disease management
Pandemic COVID-19
Covid-19
Cross-Sectional Studies
Female
Healthcare avoidance
Humans
Longitudinal Studies
Male
Middle Aged
Pandemics
SARS-CoV-2
Surveys and Questionnaires
Telehealth use
Telemedicine

Semantics

Type Source Name
disease MESH Covid-19 pandemic
disease MESH chronic diseases
disease MESH ADPKD
disease MESH complications
disease VO USA
disease MESH cysts
disease MESH intracranial aneurysms
disease IDO blood
disease MESH cystic kidney
drug DRUGBANK Tolvaptan
drug DRUGBANK Octreotide
drug DRUGBANK Somatostatin
drug DRUGBANK Serine
disease MESH ESRD
disease MESH emergency
drug DRUGBANK Coenzyme M
disease VO protocol
drug DRUGBANK Cysteamine
drug DRUGBANK Creatinine
disease MESH contraindications
disease VO volume
disease VO population
disease MESH infections
disease MESH lifestyle
disease IDO infection
disease IDO symptom
disease VO age
disease MESH hypertension
disease VO vaccinated
disease VO frequency
disease VO organ
disease MESH Kidney stones
disease MESH Urinary tract infection
disease VO report
drug DRUGBANK Methionine
disease MESH polycystic kidney
drug DRUGBANK L-Phenylalanine
disease VO viable
disease MESH chronic pain
disease MESH morbidity
disease IDO country
drug DRUGBANK Glutamic Acid
disease MESH kidney disease
disease MESH non communicable diseases
disease MESH heart failure
disease MESH Left ventricular hypertrophy
drug DRUGBANK Sulfasalazine
disease MESH comorbidity
disease MESH kidney failure

Original Article

(Visited 2 times, 1 visits today)